These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15122070)

  • 1. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
    Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
    Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
    Wade Calcutt M; Lee W; Puzanov I; Rothenberg ML; Hachey DL
    J Mass Spectrom; 2008 Jan; 43(1):42-52. PubMed ID: 17683023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).
    Buhrow SA; Reid JM; Jia L; McGovern RM; Covey JM; Kobs DJ; Grossi IM; Ames MM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(1):56-62. PubMed ID: 16730244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
    Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers.
    Rahman KM; James CH; Thurston DE
    Nucleic Acids Res; 2011 Jul; 39(13):5800-12. PubMed ID: 21427082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats.
    Reid JM; Buhrow SA; Kuffel MJ; Jia L; Spanswick VJ; Hartley JA; Thurston DE; Tomaszewski JE; Ames MM
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):777-86. PubMed ID: 21188379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.
    Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE
    Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assay combining high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences.
    Narayanaswamy M; Griffiths WJ; Howard PW; Thurston DE
    Anal Biochem; 2008 Mar; 374(1):173-81. PubMed ID: 18082123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
    Wilson SC; Howard PW; Forrow SM; Hartley JA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 1999 Oct; 42(20):4028-41. PubMed ID: 10514273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501).
    Cheung A; Struble E; He J; Yang C; Wang E; Thurston DE; Liu P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):10-20. PubMed ID: 15994138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.
    Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA
    Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
    Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.
    Rahman KM; Thompson AS; James CH; Narayanaswamy M; Thurston DE
    J Am Chem Soc; 2009 Sep; 131(38):13756-66. PubMed ID: 19725510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
    Hadjivassileva T; Thurston DE; Taylor PW
    J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
    Hartley JA; Flynn MJ; Bingham JP; Corbett S; Reinert H; Tiberghien A; Masterson LA; Antonow D; Adams L; Chowdhury S; Williams DG; Mao S; Harper J; Havenith CEG; Zammarchi F; Chivers S; van Berkel PH; Howard PW
    Sci Rep; 2018 Jul; 8(1):10479. PubMed ID: 29992976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of molecular dynamics simulations to evaluate the DNA sequence-selectivity of G-A cross-linking PBD-duocarmycin dimers.
    Jackson PJM; Rahman KM; Thurston DE
    Bioorg Med Chem Lett; 2017 Jan; 27(1):102-108. PubMed ID: 27889454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.
    Guichard SM; Macpherson JS; Thurston DE; Jodrell DI
    Eur J Cancer; 2005 Aug; 41(12):1811-8. PubMed ID: 16046116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
    Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
    BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.